CERT Certara

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions.

Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to modeling and analysis of clinical trial results.

"This reusable suite of shared platform services enables us to both integrate with and launch new interoperable software solutions that span our customers’ workflows from discovery to submission," said Max Kanevsky, Chief Technology Officer of Certara Data Sciences Software. "Clients want easy-to-use, integrated solutions that speed time to insight for novel drug development problems," said William F. Feehery, CEO of Certara. "Certara Cloud enhances the customer experience for clients that use multiple Certara products."

Certara Cloud delivers value and unique capabilities across several areas of immediate benefit and lays the foundation for future advanced operations, including:

  • Real-time collaboration across internal teams and external partners with reduced friction in deployment, licensing, and technical implementation.
  • Centralized security and IT administration, leveraging Single Sign On and cross-product user management and auditing functions.
  • Best practices documentation and media-rich educational resources from thought leaders spanning all stages of drug development including complimentary access to the gold standard PK/PD e-book, Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications.
  • Cross-functional insights and benchmarks for clients, derived from following their drug candidate across its various stops in the Certara ecosystem.

Certara Cloud is following a phased roll-out over 2024 with over 1,500 client-specific portals already prepared and is currently in use by fifteen of the top 30 biopharmaceutical companies. Customers are welcome to register individually for their Certara ID via .

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Certara Contact:

Sheila Rocchio

Media Contact:

Alyssa Horowitz



EN
16/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE

Certara Reports First Quarter 2024 Financial Results

Certara Reports First Quarter 2024 Financial Results Reiterates Full Year 2024 Financial Guidance PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024. First Quarter Highlights: Revenue was $96.7 million, compared to $90.3 million in the first quarter of 2023, representing growth of 7%.  Software revenue was $39.3 million, compared to $33.0 million in the first quarter of 2023, representing growth of 19%.Services revenue was $57.3 million, flat co...

 PRESS RELEASE

Certara Launches Cloud Platform to Further Unify its End-to-End Scient...

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions. Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to modeling and analysis of clinical trial results. "This reusable suite of shared platform services enables us to bo...

 PRESS RELEASE

Certara to Report First Quarter 2024 Financial Results on May 7th, 202...

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to It is recommended to register at least one day ...

 PRESS RELEASE

Certara Reports Fourth Quarter 2023 Financial Results

Certara Reports Fourth Quarter 2023 Financial Results Provides Full Year 2024 Financial Guidance PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: Revenue was $88.0 million, compared to $86.6 million in the fourth quarter of 2022, representing growth of 2% over the fourth quarter of 2022.Strong sequential growth with record software bookings and broad-based recovery in technology enabled services bookings durin...

 PRESS RELEASE

Certara to Report Fourth Quarter and Full Year 2023 Financial Results ...

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are requi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch